Best Practice & Research Clinical Rheumatology
Volume 24, Issue 4 , Pages 527-540 , August 2010

Therapeutic opportunities in fibroblasts in inflammatory arthritis

  • Marianne Niedermeier

      Affiliations

    • Institute for Experimental Musculoskeletal Medicine, University Hospital Muenster, Domagkstrasse 3, D-48149 Münster, Germany
    • Internal Medicine D, Department of Nephrology and Rheumatology, University Hospital Muenster, Domagkstrasse 3, D-48149 Münster, Germany
    • Tel.: +49 251 835 7799; Fax: +49 251 835 7462.
    • ,
  • Thomas Pap

      Affiliations

    • Institute for Experimental Musculoskeletal Medicine, University Hospital Muenster, Domagkstrasse 3, D-48149 Münster, Germany
    • Corresponding Author InformationCorresponding author. Tel.: +49 251 835 7799; Fax: +49 251 835 7462.
    • ,
  • Adelheid Korb

      Affiliations

    • Internal Medicine D, Department of Nephrology and Rheumatology, University Hospital Muenster, Domagkstrasse 3, D-48149 Münster, Germany
    • Tel.: +49 251 835 7799; Fax: +49 251 835 7462.

References 

  1. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature. 2003;423:356–361
  2. Pap T, Muller-Ladner U, Gay RE, Gay S. Fibroblast biology. Role of synovial fibroblasts in the pathogenesis of rheumatoid arthritis. Arthritis Research. 2000;2:361–367
  3. Pap T, Meinecke I, Muller-Ladner U, Gay S. Are fibroblasts involved in joint destruction?. Annals of the Rheumatic Diseases. 2005;64(Suppl. 4):iv52–iv54
  4. Huber LC, Distler O, Tarner I, et al. Synovial fibroblasts: key players in rheumatoid arthritis. Rheumatology (Oxford). 2006;45:669–675
  5. Mor A, Abramson SB, Pillinger MH. The fibroblast-like synovial cell in rheumatoid arthritis: a key player in inflammation and joint destruction. Clinical Immunology (Orlando, Fla.). 2005;115:118–128
  6. Fassbender HG. Histomorphological basis of articular cartilage destruction in rheumatoid arthritis. Collagen and Related Research. 1983;3:141–155
  7. Lafyatis R, Remmers EF, Roberts AB, et al. Anchorage-independent growth of synoviocytes from arthritic and normal joints. Stimulation by exogenous platelet-derived growth factor and inhibition by transforming growth factor-beta and retinoids. The Journal of Clinical Investigation. 1989;83:1267–1276
  8. Muller-Ladner U, Kriegsmann J, Franklin BN, et al. Synovial fibroblasts of patients with rheumatoid arthritis attach to and invade normal human cartilage when engrafted into SCID mice. The American Journal of Pathology. 1996;149:1607–1615
  9. Karouzakis E, Gay RE, Michel BA, et al. DNA hypomethylation in rheumatoid arthritis synovial fibroblasts. Arthritis and Rheumatism. 2009;60:3613–3622
  10. Muller-Ladner U, Gay RE, Gay S. Activation of synoviocytes. Current Opinion in Rheumatology. 2000;12:186–194
  11. Trabandt A, Gay RE, Gay S. Oncogene activation in rheumatoid synovium. Acta Pathologica, Microbiologica, et Immunologica Scandinavica. 1992;100:861–875
  12. Aicher WK, Heer AH, Trabandt A, et al. Overexpression of zinc-finger transcription factor Z-225/Egr-1 in synoviocytes from rheumatoid arthritis patients. Journal of Immunology. 1994;152:5940–5948
  13. Trabandt A, Aicher WK, Gay RE, et al. Spontaneous expression of immediately-early response genes c-fos and egr-1 in collagenase-producing rheumatoid synovial fibroblasts. Rheumatology International. 1992;12:53–59
  14. Dooley S, Herlitzka I, Hanselmann R, et al. Constitutive expression of c-fos and c-jun, overexpression of ets-2, and reduced expression of metastasis suppressor gene nm23-H1 in rheumatoid arthritis. Annals of the Rheumatic Diseases. 1996;55:298–304
  15. Muller-Ladner U, Kriegsmann J, Gay RE, Gay S. Oncogenes in rheumatoid arthritis. Rheumatic Diseases Clinics of North America. 1995;21:675–690
  16. Pap T, Nawrath M, Heinrich J, et al. Cooperation of Ras- and c-Myc-dependent pathways in regulating the growth and invasiveness of synovial fibroblasts in rheumatoid arthritis. Arthritis and Rheumatism. 2004;50:2794–2802
  17. Yamamoto A, Fukuda A, Seto H, et al. Suppression of arthritic bone destruction by adenovirus-mediated dominant-negative Ras gene transfer to synoviocytes and osteoclasts. Arthritis and Rheumatism. 2003;48:2682–2692
  18. Firestein GS, Echeverri F, Yeo M, et al. Somatic mutations in the p53 tumor suppressor gene in rheumatoid arthritis synovium. Proceedings of the National Academy of Sciences of the United States of America. 1997;94:10895–10900
  19. Pap T, Aupperle KR, Gay S, et al. Invasiveness of synovial fibroblasts is regulated by p53 in the SCID mouse in vivo model of cartilage invasion. Arthritis and Rheumatism. 2001;44:676–681
  20. Cha HS, Rosengren S, Boyle DL, Firestein GS. PUMA regulation and proapoptotic effects in fibroblast-like synoviocytes. Arthritis and Rheumatism. 2006;54:587–592
  21. Pap T, Franz JK, Hummel KM, et al. Activation of synovial fibroblasts in rheumatoid arthritis: lack of Expression of the tumour suppressor PTEN at sites of invasive growth and destruction. Arthritis Research. 2000;2:59–64
  22. Di CA, Kotsi P, Peng YF, et al. Impaired Fas response and autoimmunity in Pten+/− mice. Science. 1999;285:2122–2125
  23. Baier A, Meineckel I, Gay S, Pap T. Apoptosis in rheumatoid arthritis. Current Opinion in Rheumatology. 2003;15:274–279
  24. Pope RM. Apoptosis as a therapeutic tool in rheumatoid arthritis. Nature Reviews. Immunology. 2002;2:527–535
  25. Drynda A, Quax PH, Neumann M, et al. Gene transfer of tissue inhibitor of metalloproteinases-3 reverses the inhibitory effects of TNF-alpha on Fas-induced apoptosis in rheumatoid arthritis synovial fibroblasts. Journal of Immunology. 2005;174:6524–6531
  26. Morel J, Audo R, Hahne M, Combe B. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces rheumatoid arthritis synovial fibroblast proliferation through mitogen-activated protein kinases and phosphatidylinositol 3-kinase/Akt. The Journal of Biological Chemistry. 2005;280:15709–15718
  27. Miranda-Carus ME, Balsa A, ito-Miguel M, et al. Rheumatoid arthritis synovial fluid fibroblasts express TRAIL-R2 (DR5) that is functionally active. Arthritis and Rheumatism. 2004;50:2786–2793
  28. Ichikawa K, Liu W, Fleck M, et al. TRAIL-R2 (DR5) mediates apoptosis of synovial fibroblasts in rheumatoid arthritis. Journal of Immunology. 2003;171:1061–1069
  29. Wang J, Li C, Liu Y, et al. JAB1 determines the response of rheumatoid arthritis synovial fibroblasts to tumor necrosis factor-alpha. The American Journal of Pathology. 2006;169:889–902
  30. Wang CR, Shiau AL, Chen SY, et al. Amelioration of collagen-induced arthritis in rats by adenovirus-mediated PTEN gene transfer. Arthritis and Rheumatism. 2008;58:1650–1656
  31. Hasunuma T, Kayagaki N, Asahara H, et al. Accumulation of soluble Fas in inflamed joints of patients with rheumatoid arthritis. Arthritis and Rheumatism. 1997;40:80–86
  32. Schedel J, Gay RE, Kuenzler P, et al. FLICE-inhibitory protein expression in synovial fibroblasts and at sites of cartilage and bone erosion in rheumatoid arthritis. Arthritis and Rheumatism. 2002;46:1512–1518
  33. Kataoka T. The caspase-8 modulator c-FLIP. Critical Reviews in Immunology. 2005;25:31–58
  34. Palao G, Santiago B, Galindo M, et al. Down-regulation of FLIP sensitizes rheumatoid synovial fibroblasts to Fas-mediated apoptosis. Arthritis and Rheumatism. 2004;50:2803–2810
  35. Meinecke I, Cinski A, Baier A, et al. Modification of nuclear PML protein by SUMO-1 regulates Fas-induced apoptosis in rheumatoid arthritis synovial fibroblasts. Proceedings of the National Academy of Sciences of the United States of America. 2007;104:5073–5078
  36. Perlman H, Georganas C, Pagliari LJ, et al. Bcl-2 expression in synovial fibroblasts is essential for maintaining mitochondrial homeostasis and cell viability. Journal of Immunology. 2000;164:5227–5235
  37. Kurowska M, Rudnicka W, Kontny E, et al. Fibroblast-like synoviocytes from rheumatoid arthritis patients express functional IL-15 receptor complex: endogenous IL-15 in autocrine fashion enhances cell proliferation and expression of Bcl-x(L) and Bcl-2. Journal of Immunology. 2002;169:1760–1767
  38. Liu H, Eksarko P, Temkin V, et al. Mcl-1 is essential for the survival of synovial fibroblasts in rheumatoid arthritis. Journal of Immunology. 2005;175:8337–8345
  39. Liu H, Huang Q, Shi B, et al. Regulation of Mcl-1 expression in rheumatoid arthritis synovial macrophages. Arthritis and Rheumatism. 2006;54:3174–3181
  40. Keffer J, Probert L, Cazlaris H, et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO Journal. 1991;10:4025–4031
  41. Zwerina J, Redlich K, Polzer K, et al. TNF-induced structural joint damage is mediated by IL-1. Proceedings of the National Academy of Sciences of the United States of America. 2007;104:11742–11747
  42. Hayer S, Pundt N, Peters MA, et al. PI3K{gamma} regulates cartilage damage in chronic inflammatory arthritis. FASEB Journal. 2009;23:4288–4298
  43. Abeles AM, Pillinger MH. The role of the synovial fibroblast in rheumatoid arthritis: cartilage destruction and the regulation of matrix metalloproteinases. Bulletin of the NYU Hospital for Joint Diseases. 2006;64:20–24
  44. Bucala R, Ritchlin C, Winchester R, Cerami A. Constitutive production of inflammatory and mitogenic cytokines by rheumatoid synovial fibroblasts. The Journal of Experimental Medicine. 1991;173:569–574
  45. Ritchlin C, Dwyer E, Bucala R, Winchester R. Sustained and distinctive patterns of gene activation in synovial fibroblasts and whole synovial tissue obtained from inflammatory synovitis. Scandinavian Journal of Immunology. 1994;40:292–298
  46. Hirth A, Skapenko A, Kinne RW, et al. Cytokine mRNA and protein expression in primary-culture and repeated-passage synovial fibroblasts from patients with rheumatoid arthritis. Arthritis Research. 2002;4:117–125
  47. Fiorito S, Magrini L, Adrey J, et al. Inflammatory status and cartilage regenerative potential of synovial fibroblasts from patients with osteoarthritis and chondropathy. Rheumatology (Oxford). 2005;44:164–171
  48. Hwang SY, Kim JY, Kim KW, et al. IL-17 induces production of IL-6 and IL-8 in rheumatoid arthritis synovial fibroblasts via NF-kappaB- and PI3-kinase/Akt-dependent pathways. Arthritis Research & Therapy. 2004;6:R120–R128
  49. Nanki T, Nagasaka K, Hayashida K, et al. Chemokines regulate IL-6 and IL-8 production by fibroblast-like synoviocytes from patients with rheumatoid arthritis. Journal of Immunology. 2001;167:5381–5385
  50. Tamura T, Udagawa N, Takahashi N, et al. Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. Proceedings of the National Academy of Sciences of the United States of America. 1993;90:11924–11928
  51. Mihara M, Kasutani K, Okazaki M, et al. Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. International Immunopharmacology. 2005;5:1731–1740
  52. Hintzen C, Quaiser S, Pap T, et al. Induction of CCL13 expression in synovial fibroblasts highlights a significant role of oncostatin M in rheumatoid arthritis. Arthritis and Rheumatism. 2009;60:1932–1943
  53. Ritchlin C. Fibroblast biology. Effector signals released by the synovial fibroblast in arthritis. Arthritis Research. 2000;2:356–360
  54. Murphy PM, Tiffany HL. Cloning of complementary DNA encoding a functional human interleukin-8 receptor. Science. 1991;253:1280–1283
  55. Rubbert A, Combadiere C, Ostrowski M, et al. Dendritic cells express multiple chemokine receptors used as coreceptors for HIV entry. Journal of Immunology. 1998;160:3933–3941
  56. Buckley CD, Amft N, Bradfield PF, et al. Persistent induction of the chemokine receptor CXCR4 by TGF-beta 1 on synovial T cells contributes to their accumulation within the rheumatoid synovium. Journal of Immunology. 2000;165:3423–3429
  57. Cho CS, Cho ML, Min SY, et al. CD40 engagement on synovial fibroblast up-regulates production of vascular endothelial growth factor. Journal of Immunology. 2000;164:5055–5061
  58. Nanki T, Hayashida K, El-Gabalawy HS, et al. Stromal cell-derived factor-1-CXC chemokine receptor 4 interactions play a central role in CD4+T cell accumulation in rheumatoid arthritis synovium. Journal of Immunology. 2000;165:6590–6598
  59. Ruth JH, Haas CS, Park CC, et al. CXCL16-mediated cell recruitment to rheumatoid arthritis synovial tissue and murine lymph nodes is dependent upon the MAPK pathway. Arthritis and Rheumatism. 2006;54:765–778
  60. Pritchard J, Tsui S, Horst N, et al. Synovial fibroblasts from patients with rheumatoid arthritis, like fibroblasts from Graves’ disease, express high levels of IL-16 when treated with Igs against insulin-like growth factor-1 receptor. Journal of Immunology. 2004;173:3564–3569
  61. Franz JK, Kolb SA, Hummel KM, et al. Interleukin-16, produced by synovial fibroblasts, mediates chemoattraction for CD4+T lymphocytes in rheumatoid arthritis. European Journal of Immunology. 1998;28:2661–2671
  62. Harada S, Yamamura M, Okamoto H, et al. Production of interleukin-7 and interleukin-15 by fibroblast-like synoviocytes from patients with rheumatoid arthritis. Arthritis and Rheumatism. 1999;42:1508–1516
  63. Burger JA, Zvaifler NJ, Tsukada N, et al. Fibroblast-like synoviocytes support B-cell pseudoemperipolesis via a stromal cell-derived factor-1- and CD106 (VCAM-1)-dependent mechanism. The Journal of Clinical Investigation. 2001;107:305–315
  64. Reparon-Schuijt CC, van Esch WJ, van KC, et al. Regulation of synovial B cell survival in rheumatoid arthritis by vascular cell adhesion molecule 1 (CD106) expressed on fibroblast-like synoviocytes. Arthritis and Rheumatism. 2000;43:1115–1121
  65. Hayashida K, Shimaoka Y, Ochi T, Lipsky PE. Rheumatoid arthritis synovial stromal cells inhibit apoptosis and up-regulate Bcl-xL expression by B cells in a CD49/CD29-CD106-dependent mechanism. Journal of Immunology. 2000;164:1110–1116
  66. Pap T. Direct interaction of immunoglobulins with synovial fibroblasts: a missing link in the pathogenesis of rheumatoid arthritis?. Arthritis Research & Therapy. 2005;7:44–46
  67. Schett G, Tohidast-Akrad M, Smolen JS, et al. Activation, differential localization, and regulation of the stress-activated protein kinases, extracellular signal-regulated kinase, c-JUN N-terminal kinase, and p38 mitogen-activated protein kinase, in synovial tissue and cells in rheumatoid arthritis. Arthritis and Rheumatism. 2000;43:2501–2512
  68. Nishikawa M, Myoui A, Tomita T, et al. Prevention of the onset and progression of collagen-induced arthritis in rats by the potent p38 mitogen-activated protein kinase inhibitor FR167653. Arthritis and Rheumatism. 2003;48:2670–2681
  69. Ohori M. ERK inhibitors as a potential new therapy for rheumatoid arthritis. Drug News Perspectives. 2008;21:245–250
  70. Lee YR, Kweon SH, Kwon KB, et al. Inhibition of IL-1beta-mediated inflammatory responses by the IkappaB alpha super-repressor in human fibroblast-like synoviocytes. Biochemical and Biophysical Research Communications. 2009;378:90–94
  71. Mbalaviele G, Sommers CD, Bonar SL, et al. A novel, highly selective, tight binding IkappaB kinase-2 (IKK-2) inhibitor: a tool to correlate IKK-2 activity to the fate and functions of the components of the nuclear factor-kappaB pathway in arthritis-relevant cells and animal models. The Journal of Pharmacology and Experimental Therapeutics. 2009;329:14–25
  72. Wen D, Nong Y, Morgan JG, et al. A selective small molecule IkappaB Kinase beta inhibitor blocks nuclear factor kappaB-mediated inflammatory responses in human fibroblast-like synoviocytes, chondrocytes, and mast cells. The Journal of Pharmacology and Experimental Therapeutics. 2006;317:989–1001
  73. Gravallese EM, Manning C, Tsay A, et al. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis and Rheumatism. 2000;43:250–258
  74. Shigeyama Y, Pap T, Kunzler P, et al. Expression of osteoclast differentiation factor in rheumatoid arthritis. Arthritis and Rheumatism. 2000;43:2523–2530
  75. Rinaldi N, Schwarz-Eywill M, Weis D, et al. Increased expression of integrins on fibroblast-like synoviocytes from rheumatoid arthritis in vitro correlates with enhanced binding to extracellular matrix proteins. Annals of the Rheumatic Diseases. 1997;56:45–51
  76. Rinaldi N, Barth T, Henne C, et al. Synoviocytes in chronic synovitis in situ and cytokine stimulated synovial cells in vitro neo-express alpha 1, alpha 3 and alpha 5 chains of beta 1 integrins. Virchows Archiv. 1994;425:171–180
  77. Nikkari L, Aho H, Yli-Jama T, et al. Expression of integrin family of cell adhesion receptors in rheumatoid synovium. Alpha 6 integrin subunit in normal and hyperplastic synovial lining cell layer. The American Journal of Pathology. 1993;142:1019–1027
  78. Agarwal SK, Brenner MB. Role of adhesion molecules in synovial inflammation. Current Opinion in Rheumatology. 2006;18:268–276
  79. El-Gabalawy H, Wilkins J. Beta 1 (CD29) integrin expression in rheumatoid synovial membranes: an immunohistologic study of distribution patterns. The Journal of Rheumatology. 1993;20:231–237
  80. Muller-Ladner U, Elices MJ, Kriegsmann JB, et al. Alternatively spliced CS-1 fibronectin isoform and its receptor VLA-4 in rheumatoid arthritis synovium. The Journal of Rheumatology. 1997;24:1873–1880
  81. Wunrau C, Schnaeker EM, Freyth K, et al. Establishment of a matrix-associated transepithelial resistance invasion assay to precisely measure the invasive potential of synovial fibroblasts. Arthritis and Rheumatism. 2009;60:2606–2611
  82. Wang AZ, Wang JC, Fisher GW, Diamond HS. Interleukin-1beta-stimulated invasion of articular cartilage by rheumatoid synovial fibroblasts is inhibited by antibodies to specific integrin receptors and by collagenase inhibitors. Arthritis and Rheumatism. 1997;40:1298–1307
  83. Schwartz MA. Integrins, oncogenes, and anchorage independence. The Journal of Cell Biology. 1997;139:575–578
  84. Dike LE, Farmer SR. Cell adhesion induces expression of growth-associated genes in suspension-arrested fibroblasts. Proceedings of the National Academy of Sciences of the United States of America. 1988;85:6792–6796
  85. Dike LE, Ingber DE. Integrin-dependent induction of early growth response genes in capillary endothelial cells. Journal of Cell Science. 1996;109(Pt 12):2855–2863
  86. Kriegsmann J, Keyszer GM, Geiler T, et al. Expression of vascular cell adhesion molecule-1 mRNA and protein in rheumatoid synovium demonstrated by in situ hybridization and immunohistochemistry. Laboratory Investigation. 1995;72:209–214
  87. Iigo Y, Takashi T, Tamatani T, et al. ICAM-1-dependent pathway is critically involved in the pathogenesis of adjuvant arthritis in rats. Journal of Immunology. 1991;147:4167–4171
  88. Kakimoto K, Nakamura T, Ishii K, et al. The effect of anti-adhesion molecule antibody on the development of collagen-induced arthritis. Cell Immunology. 1992;142:326–337
  89. Bullard DC, Hurley LA, Lorenzo I, et al. Reduced susceptibility to collagen-induced arthritis in mice deficient in intercellular adhesion molecule-1. Journal of Immunology. 1996;157:3153–3158
  90. McCachren SS, Lightner VA. Expression of human tenascin in synovitis and its regulation by interleukin-1. Arthritis and Rheumatism. 1992;35:1185–1196
  91. Midwood K, Sacre S, Piccinini AM, et al. Tenascin-C is an endogenous activator of Toll-like receptor 4 that is essential for maintaining inflammation in arthritic joint disease. Nature Medicine. 2009;15:774–780
  92. Johnson BA, Haines GK, Harlow LA, Koch AE. Adhesion molecule expression in human synovial tissue. Arthritis and Rheumatism. 1993;36:137–146
  93. Bauer S, Jendro MC, Wadle A, et al. Fibroblast activation protein is expressed by rheumatoid myofibroblast-like synoviocytes. Arthritis Research & Therapy. 2006;8:R171
  94. Lefevre S, Knedla A, Tennie C, et al. Synovial fibroblasts spread rheumatoid arthritis to unaffected joints. Nature Medicine. 2009;15:1414–1420
  95. Kiener HP, Lee DM, Agarwal SK, Brenner MB. Cadherin-11 induces rheumatoid arthritis fibroblast-like synoviocytes to form lining layers in vitro. The American Journal of Pathology. 2006;168:1486–1499
  96. Kiener HP, Niederreiter B, Lee DM, et al. Cadherin 11 promotes invasive behavior of fibroblast-like synoviocytes. Arthritis and Rheumatism. 2009;60:1305–1310
  97. Lee DM, Kiener HP, Agarwal SK, et al. Cadherin-11 in synovial lining formation and pathology in arthritis. Science. 2007;315:1006–1010
  98. Nagase H, Woessner JF. Matrix metalloproteinases. The Journal of Biological Chemistry. 1999;274:21491–21494
  99. Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovascular Research. 2006;69:562–573
  100. Martel-Pelletier J, Welsch DJ, Pelletier JP. Metalloproteases and inhibitors in arthritic diseases. Best Practice & Research. Clinical Rheumatology. 2001;15:805–829
  101. Wolfsberg TG, Primakoff P, Myles DG, White JM. ADAM, a novel family of membrane proteins containing A Disintegrin And Metalloprotease domain: multipotential functions in cell-cell and cell-matrix interactions. The Journal of Cell Biology. 1995;131:275–278
  102. Kaushal GP, Shah SV. The new kids on the block: ADAMTSs, potentially multifunctional metalloproteinases of the ADAM family. The Journal of Clinical Investigation. 2000;105:1335–1337
  103. Tortorella MD, Burn TC, Pratta MA, et al. Purification and cloning of aggrecanase-1: a member of the ADAMTS family of proteins. Science. 1999;284:1664–1666
  104. Firestein GS, Paine MM. Stromelysin and tissue inhibitor of metalloproteinases gene expression in rheumatoid arthritis synovium. The American Journal of Pathology. 1992;140:1309–1314
  105. Okada Y, Gonoji Y, Nakanishi I, et al. Immunohistochemical demonstration of collagenase and tissue inhibitor of metalloproteinases (TIMP) in synovial lining cells of rheumatoid synovium. Virchows Archiv. B, Cell Pathology including Molecular Pathology. 1990;59:305–312
  106. Cunnane G, FitzGerald O, Hummel KM, et al. Collagenase, cathepsin B and cathepsin L gene expression in the synovial membrane of patients with early inflammatory arthritis. Rheumatology (Oxford). 1999;38:34–42
  107. Okada Y, Takeuchi N, Tomita K, et al. Immunolocalization of matrix metalloproteinase 3 (stromelysin) in rheumatoid synovioblasts (B cells): correlation with rheumatoid arthritis. Annals of the Rheumatic Diseases. 1989;48:645–653
  108. Tetlow LC, Lees M, Ogata Y, et al. Differential expression of gelatinase B (MMP-9) and stromelysin-1 (MMP-3) by rheumatoid synovial cells in vitro and in vivo. Rheumatology International. 1993;13:53–59
  109. Wernicke D, Seyfert C, Hinzmann B, Gromnica-Ihle E. Cloning of collagenase 3 from the synovial membrane and its expression in rheumatoid arthritis and osteoarthritis. The Journal of Rheumatology. 1996;23:590–595
  110. Lindy O, Konttinen YT, Sorsa T, et al. Matrix metalloproteinase 13 (collagenase 3) in human rheumatoid synovium. Arthritis and Rheumatism. 1997;40:1391–1399
  111. Pap T, Shigeyama Y, Kuchen S, et al. Differential expression pattern of membrane-type matrix metalloproteinases in rheumatoid arthritis. Arthritis and Rheumatism. 2000;43:1226–1232
  112. Maeda S, Sawai T, Uzuki M, et al. Determination of interstitial collagenase (MMP-1) in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases. 1995;54:970–975
  113. Tolboom TC, Pieterman E, van der Laan WH, et al. Invasive properties of fibroblast-like synoviocytes: correlation with growth characteristics and expression of MMP-1, MMP-3, and MMP-10. Annals of the Rheumatic Diseases. 2002;61:975–980
  114. Rutkauskaite E, Zacharias W, Schedel J, et al. Ribozymes that inhibit the production of matrix metalloproteinase 1 reduce the invasiveness of rheumatoid arthritis synovial fibroblasts. Arthritis and Rheumatism. 2004;50:1448–1456
  115. Echtermeyer F, Bertrand J, Dreier R, et al. Syndecan-4 regulates ADAMTS-5 activation and cartilage breakdown in osteoarthritis. Nature Medicine. 2009;15:1072–1076
  116. Stanczyk J, Pedrioli DM, Brentano F, et al. Altered expression of MicroRNA in synovial fibroblasts and synovial tissue in rheumatoid arthritis. Arthritis and Rheumatism. 2008;58:1001–1009
  117. Hoberg M, Rudert M, Pap T, et al. Attachment to laminin-111 facilitates transforming growth factor beta-induced expression of matrix metalloproteinase-3 in synovial fibroblasts. Annals of the Rheumatic Diseases. 2007;66:446–451
  118. Brinckerhoff CE, Auble DT. Regulation of collagenase gene expression in synovial fibroblasts. Annals of the New York Academy of Sciences. 1990;580:355–374
  119. Dayer JM, Beutler B, Cerami A. Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. The Journal of Experimental Medicine. 1985;162:2163–2168
  120. Kuiper S, Joosten LA, Bendele AM, et al. Different roles of tumour necrosis factor alpha and interleukin 1 in murine streptococcal cell wall arthritis. Cytokine. 1998;10:690–702
  121. Jovanovic DV, Martel-Pelletier J, Di Battista JA, et al. Stimulation of 92-kd gelatinase (matrix metalloproteinase 9) production by interleukin-17 in human monocyte/macrophages: a possible role in rheumatoid arthritis. Arthritis and Rheumatism. 2000;43:1134–1144
  122. Ravanti L, Hakkinen L, Larjava H, et al. Transforming growth factor-beta induces collagenase-3 expression by human gingival fibroblasts via p38 mitogen-activated protein kinase. The Journal of Biological Chemistry. 1999;274:37292–37300
  123. Bond M, Fabunmi RP, Baker AH, Newby AC. Synergistic upregulation of metalloproteinase-9 by growth factors and inflammatory cytokines: an absolute requirement for transcription factor NF-kappa B. FEBS Letters. 1998;435:29–34
  124. Senolt L, Grigorian M, Lukanidin E, et al. S100A4 is expressed at site of invasion in rheumatoid arthritis synovium and modulates production of matrix metalloproteinases. Annals of the Rheumatic Diseases. 2006;65:1645–1648
  125. Clark IM, Powell LK, Ramsey S, et al. The measurement of collagenase, tissue inhibitor of metalloproteinases (TIMP), and collagenase-TIMP complex in synovial fluids from patients with osteoarthritis and rheumatoid arthritis. Arthritis and Rheumatism. 1993;36:372–379
  126. DiBattista JA, Pelletier JP, Zafarullah M, et al. Coordinate regulation of matrix metalloproteases and tissue inhibitor of metalloproteinase expression in human synovial fibroblasts. The Journal of Rheumatology. Supplement. 1995;43:123–128
  127. Brew K, Dinakarpandian D, Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochimica et Biophysica Acta. 2000;1477:267–283
  128. Bode W, Fernandez-Catalan C, Grams F, et al. Insights into MMP-TIMP interactions. Annals of the New York Academy of Sciences. 1999;878:73–91
  129. van der Laan WH, Quax PH, Seemayer CA, et al. Cartilage degradation and invasion by rheumatoid synovial fibroblasts is inhibited by gene transfer of TIMP-1 and TIMP-3. Gene Therapy. 2003;10:234–242
  130. Smith MR, Kung H, Durum SK, et al. TIMP-3 induces cell death by stabilizing TNF-alpha receptors on the surface of human colon carcinoma cells. Cytokine. 1997;9:770–780
  131. Hargreaves PG, Wang F, Antcliff J, et al. Human myeloma cells shed the interleukin-6 receptor: inhibition by tissue inhibitor of metalloproteinase-3 and a hydroxamate-based metalloproteinase inhibitor. British Journal of Haematology. 1998;101:694–702
  132. Amour A, Slocombe PM, Webster A, et al. TNF-alpha converting enzyme (TACE) is inhibited by TIMP-3. FEBS Letters. 1998;435:39–44
  133. Baker AH, George SJ, Zaltsman AB, et al. Inhibition of invasion and induction of apoptotic cell death of cancer cell lines by overexpression of TIMP-3. British Journal of Cancer. 1999;79:1347–1355
  134. Baker AH, Zaltsman AB, George SJ, Newby AC. Divergent effects of tissue inhibitor of metalloproteinase-1, -2, or -3 overexpression on rat vascular smooth muscle cell invasion, proliferation, and death in vitro. TIMP-3 promotes apoptosis. The Journal of Clinical Investigation. 1998;101:1478–1487
  135. Majid MA, Smith VA, Easty DL, et al. Adenovirus mediated gene delivery of tissue inhibitor of metalloproteinases-3 induces death in retinal pigment epithelial cells. British Journal of Ophthalmology. 2002;86:97–101
  136. Keyszer GM, Heer AH, Kriegsmann J, et al. Comparative analysis of cathepsin L, cathepsin D, and collagenase messenger RNA expression in synovial tissues of patients with rheumatoid arthritis and osteoarthritis, by in situ hybridization. Arthritis and Rheumatism. 1995;38:976–984
  137. Keyszer G, Redlich A, Haupl T, et al. Differential expression of cathepsins B and L compared with matrix metalloproteinases and their respective inhibitors in rheumatoid arthritis and osteoarthritis: a parallel investigation by semiquantitative reverse transcriptase-polymerase chain reaction and immunohistochemistry. Arthritis and Rheumatism. 1998;41:1378–1387
  138. Trabandt A, Aicher WK, Gay RE, et al. Expression of the collagenolytic and Ras-induced cysteine proteinase cathepsin L and proliferation-associated oncogenes in synovial cells of MRL/I mice and patients with rheumatoid arthritis. Matrix. 1990;10:349–361
  139. Lemaire R, Huet G, Zerimech F, et al. Selective induction of the secretion of cathepsins B and L by cytokines in synovial fibroblast-like cells. British Journal of Rheumatology. 1997;36:735–743
  140. Huet G, Flipo RM, Colin C, et al. Stimulation of the secretion of latent cysteine proteinase activity by tumor necrosis factor alpha and interleukin-1. Arthritis and Rheumatism. 1993;36:772–780
  141. Schedel J, Seemayer CA, Pap T, et al. Targeting cathepsin L (CL) by specific ribozymes decreases CL protein synthesis and cartilage destruction in rheumatoid arthritis. Gene Therapy. 2004;11:1040–1047

PII: S1521-6942(10)00026-4

doi: 10.1016/j.berh.2010.02.002

Best Practice & Research Clinical Rheumatology
Volume 24, Issue 4 , Pages 527-540 , August 2010

Article Tools

* Image Usage & Resolution